Why the study?
Cancer-associated thrombosis remains a challenging aspect of managing patients with cancer.
Do direct oral anticoagulants improve treatment outcomes in patients with cancer-associated thrombosis?
Do direct oral anticoagulants improve treatment outcomes in patients with cancer-associated thrombosis?
Answers are grounded in this paper and cite their sources.
Direct oral anticoagulants are an effective, guideline-endorsed alternative to low-molecular weight heparins for managing cancer-associated thrombosis.
Cancer-associated thrombosis (CAT) remains a challenging aspect of managing patients with cancer. This review discusses evidence regarding anticoagulants in the treatment of CAT, with particular emphasis on direct oral anticoagulants (DOAC). Apixaban, rivaroxaban and edoxaban have proven attractive alternatives to low-molecular weight heparins, and interactions with medical cancer treatment does not pose a major challenge. The majority of guidelines have endorsed the use of DOAC, and we highlight points to consider when choosing the optimal anticoagulant for the individual patient.
No takes yet. Share an insight, caveat, or question.
Hellfritzsch et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: